Education
About Us
Working with TipRanks
Follow Us
X4 Pharmaceuticals (DE:48Q)
FRANKFURT:48Q
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-2.16Last Year’s EPS
11.9Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 01, 2025
|% Change Since: -42.04%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Positive
The earnings call highlights significant progress in clinical trials and strategic partnerships for global market expansion, alongside a strong financial position. However, there are challenges in sales fluctuations and market penetration in the WHIM syndrome segment. On balance, the positive developments and growth potential outweigh the current sales challenges.Company Guidance
In the first quarter of 2025, X4 Pharmaceuticals reported significant progress, with a focus on mavorixafor's development for chronic neutropenia (CN) and WHIM syndrome. The 4WARD trial, a pivotal Phase III study, is underway in over 20 countries, targeting patients with moderate to severe CN, defined as an ANC below 1000 cells per microliter and experiencing multiple infections over 12 months. The trial aims to demonstrate statistically significant ANC responses and reduced infection rates, with a robust powering of over 95% for ANC response and 90% for infection rate results. X4 expects full enrollment by late 2025 and top-line data in 2026. Additionally, the company noted cumulative XOLREMDI sales of $3.5 million since its mid-2024 launch, with new patients constituting 40% of the treated population. X4 also expanded mavorixafor's potential reach through partnerships in Europe, Australia, New Zealand, and the MENA region and anticipates EMA approval by early 2026. The company ended the quarter with nearly $90 million in cash, expecting to sustain operations into the first half of 2026.Significant Progress in Clinical Trials
X4 Pharmaceuticals has advanced the 4WARD trial, a global pivotal Phase III clinical trial for mavorixafor in chronic neutropenia (CN), with over 90% of trial sites activated and enrollment underway in over 20 countries. The trial is powered at greater than 95% for the ANC response endpoint and expects full enrollment by Q3/Q4 2025.
Patent Allowance for Mavorixafor
The US Patent Office has issued a notice of allowance for the use of mavorixafor in treating severe chronic idiopathic and autoimmune neutropenia, with the patent expected to expire in March 2041.
Partnerships for Global Expansion
X4 has completed two international partnerships: one with Norgine for commercialization in Europe, Australia, and New Zealand, and another with taiba rare for the Middle East and North Africa (MENA) region.
Strong Financial Position
X4 ended Q1 2025 with nearly $90 million in cash, supporting operations into the first half of 2026. The company reported a net income due to $28 million in license revenue from Norgine and a gain of $10.8 million on Class C warrants.
DE:48Q Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:48Q Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 25, 2025 | $8.45 | $8.09 | -4.33% |
Nov 13, 2024 | $18.07 | $16.14 | -10.71% |
Aug 08, 2024 | $17.16 | $16.86 | -1.75% |
May 07, 2024 | $31.74 | $32.88 | +3.59% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does X4 Pharmaceuticals (DE:48Q) report earnings?
X4 Pharmaceuticals (DE:48Q) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is X4 Pharmaceuticals (DE:48Q) earnings time?
X4 Pharmaceuticals (DE:48Q) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of X4 Pharmaceuticals stock?
The P/E ratio of X4 Pharmaceuticals is N/A.
What is DE:48Q EPS forecast?
DE:48Q EPS forecast for the fiscal quarter 2025 (Q2) is -2.16.